A review of single-center studies showed that prophylactic use of tocilizumab in patients receiving step-up dosing of bispecific antibodies could reduce the severity

A real-world study found that following relapse or progression after chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM), bispecific

A study assessing outcomes for the three FDA-approved BCMA-directed bispecific antibodies indicated for relapsed or refractory multiple myeloma (MM) found that linvoseltamab resulted

Between 2020 and 2021, increased mortality was observed among patients with multiple myeloma (MM), with an estimated 2500 excess deaths related to COVID-19.

Jackson Brunner, MD, of the University of Michigan, and colleagues presented the findings at the 2026 SOHO Annual Meeting. The researchers used data

The study assessed 1129 patients with relapsed or refractory multiple myeloma who initiated a bispecific antibody and had a mean length of stay

Meletios Dimopoulos MD, of the National and Kapodistrian University of Athens in Greece, and colleagues presented the findings at the 2026 SOHO Annual